Literature DB >> 9623978

Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2.

M Kato1, H Wang, V Kainulainen, M L Fitzgerald, S Ledbetter, D M Ornitz, M Bernfield.   

Abstract

The activity of fibroblast growth factor 2 (FGF-2) is stringently controlled. Inactive in undisturbed tissues, it is activated during injury and is critical for tissue repair. We find that this control can be imposed by the soluble syndecan-1 ectodomain, a heparan sulfate proteoglycan shed from cell surfaces into wound fluids. The ectodomain potently inhibits heparin-mediated FGF-2 mitogenicity because of the poorly sulfated domains in its heparin sulfate chains. Degradation of these regions by platelet heparanase produces heparin-like heparin sulfate fragments that markedly activate FGF-2 mitogenicity and are found in wound fluids. These results establish a novel physiological control for FGF-2 and suggest new ways to modulate FGF activity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9623978     DOI: 10.1038/nm0698-691

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  89 in total

Review 1.  Angiogenesis in inflammatory joint disease: a target for therapeutic intervention.

Authors:  P E Brenchley
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

2.  FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice.

Authors:  Shinichi Yoshimura; Tetsuyuki Teramoto; Michael J Whalen; Michael C Irizarry; Yasushi Takagi; Jianhua Qiu; Jun Harada; Christian Waeber; Xandra O Breakefield; Michael A Moskowitz
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

3.  Gene expression profiles identify both MyD88-independent and MyD88-dependent pathways involved in the maturation of dendritic cells mediated by heparan sulfate: a novel adjuvant.

Authors:  Meini Wu; Haixuan Wang; Jiandong Shi; Jing Sun; Zhiqing Duan; Yanhan Li; Jianfang Li; Ningzhu Hu; Yiju Wei; Yang Chen; Yunzhang Hu
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 4.  Syndecan-4: dispensable or indispensable?

Authors:  Sarah A Wilcox-Adelman; Fabienne Denhez; Tokuro Iwabuchi; Stefania Saoncella; Enzo Calautti; Paul F Goetinck
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

5.  Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis.

Authors:  Corrine R Kliment; Judson M Englert; Bernadette R Gochuico; Guoying Yu; Naftali Kaminski; Ivan Rosas; Tim D Oury
Journal:  J Biol Chem       Date:  2008-12-09       Impact factor: 5.157

Review 6.  Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.

Authors:  Ralph D Sanderson; Michael Elkin; Alan C Rapraeger; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2016-11-16       Impact factor: 5.542

7.  Syndecan-1 ectodomain shedding is regulated by the small GTPase Rab5.

Authors:  Kazutaka Hayashida; Philip D Stahl; Pyong Woo Park
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

Review 8.  Cytoplasmic interactions of syndecan-4 orchestrate adhesion receptor and growth factor receptor signalling.

Authors:  Mark D Bass; Martin J Humphries
Journal:  Biochem J       Date:  2002-11-15       Impact factor: 3.857

Review 9.  Versatile role of heparanase in inflammation.

Authors:  Rachel Goldberg; Amichay Meirovitz; Nir Hirshoren; Raanan Bulvik; Adi Binder; Ariel M Rubinstein; Michael Elkin
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

Review 10.  Heparanase and hepatocellular carcinoma: promoter or inhibitor?

Authors:  Shuo Dong; Xiong-Zhi Wu
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.